Bayer Stock News

Bayer is lobbying U.S. states to adjust their regulatory framework in its battle to wind down costly litigation over its weedkiller glyphosate, the German chemicals company's CEO said in a draft speech released on Thursday.

MYERSTOWN, Pa.--(BUSINESS WIRE)--Today, Bayer proudly celebrated the grand opening of its new 70,000 square foot expansion at its Myerstown facility, following a $44 million investment in 2022. This state-of-the-art facility is a testament to Bayer's commitment to providing trusted self-care solutions to consumers across North America while advancing meaningful engagement with the local communi...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting.

The German company cites mounting costs from lawsuits blaming Roundup for causing cancer.

Das Analysehaus Jefferies hat die Einstufung für Bayer DE000BAY0017 auf "Hold" belassen.

Bayer DE000BAY0017 wendet sich in der Hoffnung auf eine Lösung der US-Glyphosat-Rechtsstreitigkeiten erneut an das oberste Gericht des Landes.

Die US-Bank JPMorgan hat die Einstufung für Bayer DE000BAY0017 auf "Neutral" mit einem Kursziel von 25 Euro belassen.

Bayer said on Friday it was again petitioning the U.S. Supreme Court to sharply limit legal claims that its Roundup weedkiller causes cancer, seeking to avoid potentially billions of dollars in damages.